Egan Joseph R, Marí-Buyé Núria, Benítez-Cano Elia Vallejo, Costa Miquel, Wanika Linda, Chappell Michael J, Schultz Ursula, Ochs Jelena, Effenberger Manuel, Horna David, Rafiq Qasim, Goldrick Stephen
Department of Biochemical Engineering, University College London, London, UK.
School of Health and Life Sciences, National Horizons Centre, Teesside University, Darlington, UK.
Biotechnol Prog. 2025 Jun 23:e70045. doi: 10.1002/btpr.70045.
Chimeric antigen receptor (CAR) T cell therapy has tremendous potential for the treatment of cancer and other diseases. To manufacture cells of the desired quantity and quality, it is important to expand the CAR T cells ex vivo for an optimal duration. However, identifying the optimal harvest time requires knowledge of the cell concentration during the expansion period. To address this challenge, we have developed a digital shadow of CAR T cell expansion that provides a soft sensor of cell concentration in real-time. Specifically, a novel mechanistic mathematical model of cell growth within a proportional-integral-derivative (PID) controlled perfusion bioreactor has been developed using nonlinear ordinary differential equations. The model is fitted to data generated via bioreactor runs of the Aglaris FACER, in which both donor and patient cells have been expanded in two different media. Off-line data includes the initial and final cell concentrations, and online data includes the glucose and lactate concentrations as well as the perfusion rate. Training the digital shadow utilizes all the off-line and online data for each run. In contrast, real-time testing utilizes only the initial cell concentration and the available online data at the time of model fitting. Real-time testing shows that with at least 2.5 days of online data, the final cell concentration up to 2.5 days later is predicted with a mean relative error of 13% (standard deviation ≈ 6%). Informative real-time predictions of cell concentration via the digital shadow can guide decisions regarding the optimal harvest time of CAR T cells.
嵌合抗原受体(CAR)T细胞疗法在癌症和其他疾病的治疗方面具有巨大潜力。为了制造出所需数量和质量的细胞,在体外以最佳时长扩增CAR T细胞非常重要。然而,要确定最佳收获时间,需要了解扩增期间的细胞浓度。为应对这一挑战,我们开发了一种CAR T细胞扩增的数字模型,它能实时提供细胞浓度的软传感器。具体而言,利用非线性常微分方程,开发了一种在比例积分微分(PID)控制的灌注生物反应器内细胞生长的新型机理数学模型。该模型与通过Aglaris FACER生物反应器运行产生的数据拟合,其中供体细胞和患者细胞均在两种不同培养基中进行了扩增。离线数据包括初始和最终细胞浓度,在线数据包括葡萄糖和乳酸浓度以及灌注速率。训练数字模型利用每次运行的所有离线和在线数据。相比之下,实时测试仅利用模型拟合时的初始细胞浓度和可用在线数据。实时测试表明,有至少2.5天的在线数据时,可预测2.5天后的最终细胞浓度,平均相对误差为13%(标准差≈6%)。通过数字模型对细胞浓度进行实时信息预测,可为CAR T细胞最佳收获时间的决策提供指导。